About E3 ubiquitin-protein ligase RNF26
E3 ubiquitin-protein ligase RNF26 (RNF26) is a protein
from Homo sapiens identified by UniProt accession
Q9BY78, 433 residues long.
MolForge cross-references it against 0 known binders and
28 disease associations.
Target properties
| Protein name | E3 ubiquitin-protein ligase RNF26 |
| UniProt accession | Q9BY78 |
| Gene | RNF26 |
| Organism | Homo sapiens |
| Length | 433 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (28)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.34
- blood protein measurement · score 0.27
- platelet crit · score 0.20
- urinary bladder carcinoma · score 0.07
- platelet count · score 0.07
- viral disease · score 0.05
- mean corpuscular hemoglobin concentration · score 0.03
- nonpapillary renal cell carcinoma · score 0.03
- stomach neoplasm · score 0.03
- cancer · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9BY78-F1 | alphafold | PREDICTED | 75.04 | — |
Amino-acid sequence (433 residues)
MEAVYLVVNG LGLVLDVLTL VLDLNFLLVS SLLASLAWLL AFVYNLPHTV LTSLLHLGRG VLLSLLALIE AVVRFTCGGL QALCTLLYSC CSGLESLKLL GHLASHGALR SREILHRGVL NVVSSGHALL RQACDICAIA MSLVAYVINS LVNICLIGTQ NLFSLVLALW DAVTGPLWRM TDVVAAFLAH ISSSAVAMAI LLWTPCQLAL ELLASAARLL ASFVLVNLTG LVLLACVLAV TVTVLHPDFT LRLATQALSQ LHARPSYHRL REDVMRLSRL ALGSEAWRRV WSRSLQLASW PNRGGAPGAP QGDPMRVFSV RTRRQDTLPE AGRRSEAEEE EARTIRVTPV RGRERLNEEE PPGGQDPWKL LKEQEERKKC VICQDQSKTV LLLPCRHLCL CQACTEILMR HPVYHRNCPL CRRGILQTLN VYL
Explore E3 ubiquitin-protein ligase RNF26 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets